Levels of fat molecules in blood can affect relapses, disability in children
Alterations in the levels of certain fat molecules in the bloodstream are significantly associated with a higher risk of relapse…
Articles by Patricia Inacio, PhD
Brain volume loss with Ocrevus similar to healthy aging: Study
Ocrevus (ocrelizumab) reduces brain volume loss in people with relapsing forms of multiple sclerosis (MS) to levels similar…
Study examines risk factors for chronic opioid use by vets with MS
People with multiple sclerosis and a history of chronic opioid use are nearly 200 times more likely to use…
Neurologist Robert Lisak named 2023 Giant of Multiple Sclerosis
Neurologist Robert Lisak, MD, has been named a 2023 Giant of Multiple Sclerosis for his work in understanding the mechanisms…
FDA puts partial hold on trials of Merck KGaA’s evobrutinib in MS
The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on ongoing trials of evobrutinib, Merck…
Use of cannabis-based products tied to severity of MS disability, pain
Cannabis-based products are more likely to be used by multiple sclerosis (MS) patients with higher levels of disability and pain…
Half of US neurologists expect to test Briumvi in the next 6 months
Most neurologists in the U.S. are aware of the recent approval of Briumvi (ublituximab-xiiy) for the treatment of relapsing…
ModeX teams up with Merck to develop MDX-2201 vaccine for EBV
A new collaboration between ModeX Therapeutics and Merck, known as MSD outside North America, is expected to advance…
Older MS patients with stable disease may safely stop DMTs: Study
People over 60 with multiple sclerosis (MS) who have stable disease may discontinue their disease-modifying treatments (DMTs) without…
LAPIX, FDA Meeting Sets Way for LPX-TI641 Clinical Development
Lapix Therapeutics has met with the U.S. Food and Drug Administration (FDA) to determine how to advance its investigational…
Relapsing MS Therapy Briumvi Now Commercially Available in US
TG Therapeutics’ Briumvi (ublituximab-xiiy), a CD20 inhibitor recently approved for adults with relapsing forms of multiple sclerosis (MS), is…
Patient Dosing Starts in MS Phase 2 Clinical Trial of Oral SAR443820
Patient dosing has begun in a Phase 2 trial testing Denali Therapeutics‘ investigational oral RIPK1 inhibitor SAR443820 in people…
Fewer Women With MS Choosing to Stop DMT Use While Pregnant
The use of disease-modifying therapies (DMTs) by pregnant women with multiple sclerosis (MS) significantly increased over the last…
Scientists Seek to Understand Effects of Pregnancy on Immune System
Roche has teamed up with researchers in Australia to study the immune and biological mechanisms leading to better outcomes…
65% of Patients Discontinue Therapy Baclofen Within a Year in Study
About 10%-20% of people with multiple sclerosis (MS) receive baclofen to control their spasticity, but up to…
Almost No Cases Found of Celiac Disease and MS in New Analysis
Celiac disease, in which the ingestion of gluten causes the immune system to attack the lining of the small intestine,…
Frequency Names Advisory Board to Guide Remyelination Work for MS
Frequency Therapeutics has established a clinical advisory board, with experts across neuroscience fields, to help guide its small…
Sexual Dysfunction Linked to MS Fatigue, Psychological Symptoms
The severity of sexual dysfunction doesn’t seem to be associated with MRI measures of disease activity in multiple sclerosis…
Trethera to Win New US Patent for TRE-515 Chemical Composition
The U.S. Patent and Trademark Office will grant Trethera Corp. a new patent covering the composition and chemical structure…
Study Ties Antinuclear Antibodies to Inflammation, Relapses
The presence of self-reactive antibodies, typically seen in autoimmune diseases like scleroderma, may be common among patients with…
Lower MS Risk in People With High Vitamin D Levels When Young
People with high levels of free vitamin D in circulation before the age of 20 have a lower risk of…
Questionnaire May Help Women Talk About Sexual Health
While sexual problems are relatively common in women with multiple sclerosis (MS), it can still be difficult to…
NervGen Cleared to Enroll 2nd MAD Group in NVG-291 Trial
NervGen Pharma has been cleared to enroll a second group of healthy volunteers into the multiple ascending dose portion…
More Skin Cancer Reported to FDA From Patients on Certain Oral DMTs
Multiple sclerosis (MS) treatments belonging to the class of sphingosine 1-phosphate (S1P) receptor modulators — such as…
MS Australia Funds Research to Block Inflammatory T-cells From Brain
A researcher at the University of Adelaide, in Australia, has received an AU$390,000 grant (about $280,000) to investigate how inflammatory…
UPenn Neurologist Wins Barancik Prize for Innovation in MS Research
A neurology professor at the University of Pennsylvania (UPenn) has received the 2021 Barancik Prize for Innovation in MS…
Atara, Imeka Team Up to Bring Advanced Imaging to ATA188 Trial
Atara Biotherapeutics has partnered with Imeka to use its proprietary biomarker imaging technology in the ongoing EMBOLD Phase…
Minorities, Others With Depression, Asked to Join Support Group Study
Adults with multiple sclerosis (MS) and depression or anxiety, especially those of minority groups, are being asked to join…
Ascending Dosing Will Start in Trial of NVG-291 in Healthy Volunteers
NervGen Pharma has received approval to begin testing multiple ascending doses of NVG-291, its lead therapeutic candidate for…
Eye-tracking Technology Now Available in Telehealth Platform
XRHealth, a virtual reality clinic that provides treatments in patients’ homes, has integrated Tobii‘s eye-tracking technology into its…